Avidity Biosciences, Inc.
RNA · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.17 | -0.66 | -0.40 | 11.63 |
| FCF Yield | -5.51% | -3.37% | -2.78% | -1.19% |
| EV / EBITDA | -20.11 | -27.28 | -29.30 | -54.44 |
| Quality | ||||
| ROIC | -13.83% | -9.54% | -8.23% | -6.32% |
| Gross Margin | 78.84% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.90 | 1.27 | 1.08 | 0.98 |
| Growth | ||||
| Revenue 3-Year CAGR | 27.21% | 3.06% | -2.60% | 5.71% |
| Free Cash Flow Growth | -57.88% | -23.89% | -54.17% | -2.72% |
| Safety | ||||
| Net Debt / EBITDA | 1.40 | 1.90 | 1.77 | 3.72 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -432.75 | 2,093.06 | 854.35 | -231.13 |